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We read with interest the review paper on aspirin and clopidogrel resistance by Wang et al.1 
We agree that it is an emerging entity with important clinical implications. Nevertheless, we 
were surprised that very little emphasis was put on the antiplatelet agent resistance of diabetic 
patients. Only one short sentence mentioned that hyperglycaemia may decrease the 
effectiveness of antiplatelet therapy by increasing reactive oxidant species. Still the specific 
case of diabetic patients is of major interest as diabetes mellitus, especially type 2 diabetes, is 
an increasing cause of cardiovascular disease worldwide. Antiplatelet therapy is a cornerstone 
in the prevention and treatment of cardiovascular disease in any at-risk individual, including 
patients with diabetes. However, recent observations showed that patients with diabetes may 
show both acetylsalicylic acid (aspirin)2 and clopidogrel3 resistance. 
 
Placebo-controlled randomized clinical trials with aspirin in the diabetic population are scarce. 
However, post hoc analysis of large clinical studies of primary and secondary prevention 
consistently showed a less-effective cardiovascular protection by aspirin when compared with 
results observed in the non-diabetic population.2 A so-called aspirin resistance assessed by an 
in vitro platelet aggregation test was present in almost 20 % of diabetic patients, more in those 
with type 2 than in those with type 1 diabetes.2,4 Although we are at the every beginning of 
complete understanding of ‘aspirin resistance’, several potential molecular mechanisms of this 
phenomenon in diabetes have been evidenced.2,4 Diminished susceptibility of various platelet 
proteins and receptors on blood platelet membranes to acetylation, because of glycation due to 
high ambient glucose, might determine platelet ‘insensitivity to aspirin’ in diabetic patients. 
Although higher concentrations of aspirin could counteract the effects of hyperglycaemia,4 it 
has been suggested that one simple mean to overcome aspirin resistance might be to increase 
the daily dosage of aspirin from 100 to 300 mg among diabetic patients.2 However, recent 
guidelines still recommend 100–162 mg/day. 
 
Although patients with type 2 diabetes seem to benefit most from clopidogrel, a P2Y12 
receptor antagonist, compared with aspirin, they still show a reduced responsiveness to 
clopidogrel compared with non-diabetic patients.5 Insulin-treated patients with type 2 
diabetes have greater ADP-induced platelet aggregation compared with non-insulin-treated 
diabetic patients while on dual aspirin–clopidogrel oral therapy.3 The alteration of the P2Y12-
dependent pathway of platelet reactivity in patients with diabetes might partially explain the 
negative results of CHARISMA.6 In this trial, 42% of the 15 603 randomized patients had 
diabetes (17% insulin-treated), with no significant better cardiovascular protection by the 
clopidogrel plus aspirin combination vs. aspirin alone. Whether more potent P2Y12 
antagonism using a higher maintenance dose of clopidogrel or novel antagonists will be able 
to inhibit more efficiently the upregulated P2Y12 pathway in platelets of patients with type 2 
diabetes is currently under investigation. Similarly, the potential add-on value of 
thiazolidinediones (glitazones) to antiplatelet agents also deserves further studies.2 In the 
future, individualized and more aggressive antiplatelet therapeutic approaches should be 
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